Question explored with the scientific record
what is know to help with menoposal symptoms
The short version: hormone therapy is the most effective option for hot flashes and night sweats, but its risks depend on your age, timing, and the specific regimen.
The retrieved evidence consistently shows that menopausal hormone therapy (MHT) reduces hot flashes and night sweats by about 80%, with peak effect within four weeks [2]. A 2025 review calls it the "gold standard" for vasomotor symptoms, sleep disruption, and genitourinary syndrome [3]. A small 2026 study of 60 women reported 91.7% symptom relief, though quality-of-life improvement was only 41.7% [5]. The evidence is dominated by narrative reviews [1, 2, 3, 4] and one small descriptive study [5]; no large, long-term, placebo-controlled trial comparing MHT to no treatment for symptom relief alone was retrieved.
The risks are real and depend on the regimen. The Women's Health Initiative found that combined estrogen/progestin raised breast cancer risk by about 8 extra cases per 10,000 women per year, while estrogen alone was linked to 7 fewer cases per 10,000 per year [2]. Venous thromboembolism increased by about 1 extra case per 1,000 women per year at ages 50–59, and the risk doubled or tripled with age and higher BMI [2]. For women starting MHT soon after menopause, coronary artery disease deaths dropped by about 1 per 1,000 woman-years; starting it later or with existing heart disease increased adverse events [2].
Non-hormonal options have some evidence. Gabapentin at 900 mg/day reduced hot flash frequency by about 54–57% in randomized trials [7, 9, 11]. Venlafaxine at 75 mg/day reduced hot flashes by about 61% [6, 10]. Paroxetine at 20 mg reduced them by about 52% [6]. These drugs have their own side effects (drowsiness, nausea, dry mouth) and were tested mainly in breast cancer survivors or short-term trials [6, 9, 11]. Evidence for black cohosh, soy isoflavones, and vitamin E is inconsistent or shows no benefit over placebo [8, 10].
| Intervention | Approximate reduction in hot flash frequency | Key risks or limitations |
|---|---|---|
| MHT (estrogen or combined) | ~80% [2] | Breast cancer (combined regimen), VTE, timing-dependent heart risk [2] |
| Gabapentin 900 mg/day | ~54–57% [7, 9, 11] | Drowsiness, fatigue, dizziness [7, 9] |
| Venlafaxine 75 mg/day | ~61% [6, 10] | Nausea, dry mouth, appetite loss [6] |
| Paroxetine 20 mg/day | ~52% [6] | Interacts with tamoxifen; nausea [6] |
| Black cohosh / soy | No clear benefit [8, 10] | Safety data limited [8] |
My call: MHT is the most effective option for bothersome vasomotor symptoms if you are recently menopausal and have no contraindications, but the evidence base is thin on long-term, head-to-head comparisons of different regimens and doses. Non-hormonal drugs are reasonable second-line choices. Confidence: moderate.
Sources used 11
-
Understanding and Prescribing Menopausal Hormone Therapy for Vasomotor Symptoms
This educational review reports that MHT is effective first-line therapy for vasomotor symptoms and summarizes indications, formulations, routes, dosing, risks, contraindications, and shared decision-making.
DOI: 10.1891/cjnpwh-2510 -
Confronting the challenges of the menopausal transition
For most recently menopausal women, menopausal hormone therapy effectively relieves vasomotor symptoms and its benefits outweigh risks, while risks such as VTE, breast cancer, and cardiovascular events depend on age, time since menopause, BMI, and regimen.
DOI: 10.1186/s40695-015-0008-5 -
Menopausal Hormone Therapy: Clinical Guidance for Symptom Relief and Genitourinary Management
Menopausal hormone therapy remains the gold standard for managing vasomotor symptoms, mood disturbances, sleep disruption, and genitourinary syndrome of menopause when tailored to individual risk profiles, with route, dose, and progestin use individualized through shared decisio…
DOI: 10.36348/sijog.2025.v08i07.006 -
Managing Vasomotor Symptoms in Menopausal Women
A narrative review of managing menopausal vasomotor symptoms recommends lifestyle changes first, then nonhormonal drugs if needed, and reserves hormone therapy for bothersome or severe symptoms.
DOI: 10.5005/jp-journals-10032-1049 -
HORMONE REPLACEMENT THERAPY AMONG PRE-MENOPAUSAL WOMEN PATIENTS WITH SEVERE MENOPAUSAL SYMPTOMS
A descriptive study of 60 premenopausal women aged 45-50 found that 91.7% reported symptom relief from hormone replacement therapy, though quality-of-life improvement was less pronounced (41.7%) and most participants were overweight or obese.
DOI: 10.17654/2347527726002 -
Noradrenergic and serotonergic modulation to treat vasomotor symptoms
This study explores the role of noradrenergic and serotonergic modulation in treating vasomotor symptoms, particularly hot flushes, in menopausal women, highlighting the efficacy of neurotransmitter modulators as alternatives to estrogen therapy.
DOI: 10.1258/136218006775997207 -
Gabapentin for the treatment of menopausal hot flashes
This randomized controlled trial demonstrates that gabapentin significantly reduces the frequency and severity of hot flashes in postmenopausal women compared to placebo, with a notable improvement in quality of life and manageable side effects.
DOI: 10.1097/gme.0b013e3180dca175 -
Treatment strategies for hot flushes
Estrogen remains the most effective treatment for menopausal vasomotor symptoms (hot flashes), with nonhormonal options such as SSRIs/SNRIs and gabapentin providing useful alternatives; evidence for herbal/dietary phytoestrogens is inconsistent and safety data remain limited.
DOI: 10.1517/14656560902868217 -
Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E
In postmenopausal breast cancer survivors with vasomotor symptoms, gabapentin 900 mg/day reduced hot flush frequency and severity and improved sleep and quality of life significantly more than vitamin E (used as placebo) over 12 weeks, though benefits diminished after discontinu…
DOI: 10.1080/13697130902736921 -
Assessment and treatment of hot flushes and menopausal mood disturbance
A comprehensive narrative review of the assessment and treatment of hot flushes and menopausal mood disturbance, synthesizing underlying physiology, sleep and cognitive implications, and evaluating hormonal and nonhormonal treatment options for perimenopausal and postmenopausal …
DOI: 10.1016/S0193-953X(03)00045-5 -
Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial
This study demonstrates that gabapentin at a dose of 900 mg/day significantly reduces the frequency and severity of hot flashes in women with breast cancer, while a lower dose of 300 mg/day shows no significant benefit.
DOI: 10.1016/S0140-6736(05)67215-7